Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | CDK7 | P50613 | 4/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CCNH | P51946 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 2/20 | 0.39 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.38 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.38 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.38 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.38 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.38 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15224594 | 1.00 | CDK2 (0.40) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15242607 | 0.89 | PDE1C (0.43) | CDK2CDK5CDK5R1PDE9AATP1A1 | |
| SCHEMBL15242595 | 0.87 | CDK2 (0.36) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15242580 | 0.87 | CDK2 (0.38) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15242578 | 0.87 | CA1 (0.38) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15242594 | 0.87 | CA1 (0.38) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15242603 | 0.87 | CDK2 (0.37) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15242630 | 0.86 | CDK2 (0.39) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15241425 | 0.86 | CDK2 (0.41) | CDK2CDK7CDK5CDK9CDK5R1 | |
| SCHEMBL15242677 | 0.86 | CDK2 (0.39) | CDK2CDK7CDK5CDK9CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| WO-2013128029-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2013-09-06 | — | — | WO | disclosed |
| EP-2634189-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634189-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | PAK5, STK35, TESK2 | CDK2 468/4885CDK7 276/4885CDK5 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.